Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Catania – page 16

420 clinical trials in Catania, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Catania at a glance
420
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

420 trials in Catania

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Regn7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Ovarian cancer

Not yet recruiting

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Dermatitis atopic

Not yet recruiting

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Leo Pharma A/S

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Catania

What the registry says about research in the country

01 Oncology Studies

Innovative clinical trials focusing on metastatic colorectal cancer, multiple myeloma, and gastric cancer treatments. Research includes evaluation of targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatments
  • Blood Cancer Therapies
  • Gastric Cancer Interventions

Studies aim to improve treatment outcomes through targeted therapies and immunotherapy approaches.

02 Respiratory Medicine

Research initiatives examining treatments for non-small cell lung cancer, asthma, and chronic rhinosinusitis. Focus on innovative therapeutic approaches and disease management.

  • Lung Cancer Treatments
  • Asthma Control Studies
  • Nasal Polyps Management

Trials evaluate new medications and combination therapies for respiratory conditions.

03 Dermatology Research

Clinical investigations into atopic dermatitis, psoriasis, and hidradenitis suppurativa. Studies focus on novel therapeutic approaches for chronic skin conditions.

  • Inflammatory Skin Conditions
  • Autoimmune Skin Disorders
  • Chronic Skin Disease Management

Evaluation of new biological treatments and targeted therapies for skin disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.